# Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

> **NCT07070479** · PHASE2 · RECRUITING · sponsor: **Ming-Yuan Chen** · enrollment: 208 (estimated)

## Conditions studied

- Recurrent or Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** Nimotuzumab
- **DRUG:** Irinotecan liposome
- **DRUG:** S-1
- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** PD-1 Inhibitors

## Key facts

- **NCT ID:** NCT07070479
- **Lead sponsor:** Ming-Yuan Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2027-01-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070479, "Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07070479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*